Scilex Holding (SCLX) Non Operating Income (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Non Operating Income of -$13.5 million for Q1 2026, down 841.53% year-over-year from $1.8 million in Q1 2025, and down 120.74% on a QoQ basis from $65.0 million in Q4 2025.
Scilex Holding (SCLX) Non Operating Income (2022 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Non Operating Income for 5 consecutive years, with -$13.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 841.53% year-over-year to -$13.5 million; the TTM figure through Mar 2026 stood at -$43.3 million (down 350.33% YoY), while the FY2025 annual figure was -$28.0 million, down 364.64% from the prior year.
- Non Operating Income came in at -$13.5 million for Q1 2026 at Scilex Holding, down from $65.0 million in the prior quarter.
- The five-year high for Non Operating Income was $65.0 million in Q4 2025, with the low at -$71.3 million in Q3 2025.
- Average Non Operating Income over 5 years is -$538882.4, with a median of -$3.1 million recorded in 2023.
- Across the five-year window, Non Operating Income surged 817.88% in 2024 and slumped 841.53% in 2026, its largest moves.
- Year by year, Non Operating Income stood at $1.9 million in 2022, then slumped by 260.94% to -$3.1 million in 2023, then soared by 817.88% to $21.9 million in 2024, then surged by 196.53% to $65.0 million in 2025, then slumped by 120.74% to -$13.5 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$13.5 million, $65.0 million, and -$71.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -65.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -294.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -2.31 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -13.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.48 Mn |
| Dec 31, 2025 | 64.99 Mn |
| Sep 30, 2025 | -71.31 Mn |
| Jun 30, 2025 | -23.52 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 21.92 Mn |
| Sep 30, 2024 | 15.53 Mn |
| Jun 30, 2024 | -21.96 Mn |
| Mar 31, 2024 | -4.90 Mn |
| Dec 31, 2023 | -3.05 Mn |
| Sep 30, 2023 | 3.28 Mn |
| Jun 30, 2023 | -3.84 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | 1.90 Mn |
| Sep 30, 2022 | 32.11 Mn |
| Jun 30, 2022 | -6.40 Mn |
| Mar 31, 2022 | 3.03 Mn |